Dr. Edward Faber Jr. has recently submitted his survival statistics to www.myelomasurvival.com. I would like to take this opportunity to welcome him as another exceptional addition to our listing of myeloma specialists.
For patients under the care of Dr. Faber, you are 5.9 times more likely to survive 2 years and 1.6 times more likely to survive 4 years, as compared to the average SEER facility. They have provided their transplant experience over the past 5 years, and report a 2 year survival rate of 93.9%* versus the SEER data of 64.1%. They further report their 4 year survival rate of 67.8%* versus the SEER survival rate of 49.2%. Therefore, receiving care through Dr. Faber at the University of Nebraska Medical Center is another excellent find for multiple myeloma patients in the Midwest.
Since maintenance therapy with lenalidomide has only recently been adopted, the reported survival rates includes patient populations which may or may not receive maintenance lenalidomide therapy. Dr. Faber also revealed in his analysis that they are actively following the outcomes of the patients on lenalidomide maintenance in order to determine the impact of lenaldomide mainteance on these reported survival rates, especially the 4 to 5 year survival rate, which of course we all hope will improve outcomes. Dr. Faber included a very impressive bio with his information and I have included it below.
Edward A. Faber Jr., D.O., M.S., Short Biosketch:
Assistant Professor of Internal Medicine in the Hematology/Oncology Division at the University of Nebraska Medical Center since July 2009, after completing hematology / oncology fellowship training at Michigan State University.
Dr. Faber is a NCCN panel member for multiple myeloma, amyloidosis and Waldenstrom’s Macroglobulinemia. He recently has been appointed as an advisory panelist for Amyloidosis on ASCO’s Cancer.Net, Editorial Board’s Lymphoma Panel, as well as the Association of Community Cancer Centers (ACCC) Multiple Myeloma Advisory Committee. Dr. Faber also participates in the following national committees: Alliance for Clinical Trials in Oncology [CALGB] Myeloma Committee, Alliance for Clinical Trials in Oncology [CALGB] Transplant Committee, BMT CTN Myeloma Working Group, CIBMTR Myeloma Working Group. He was recently appointed as Director of UNMC’s M1/M2 Hematology/Oncology Core Course.
He is a principal investigator for all phases of clinical trials, while collaborating with cooperative groups such as Alliance, ECOG, CALGB and BMT CTN, as well as investigator initiated clinical trials. He has a special interest in clinical trials involving early, novel therapies for relapsed / refractory and high risk multiple myeloma. He also pursues translational research by applying nanomedicine to relapsed / refractory myeloma, with his current project involving the use of Pluronic polymers to augment the efficicacy of proteosome inhibitors.
Again we welcome Dr. Faber to the www.myelomasurvival.com community of skilled multiple myeloma specialists.
Best Regards and "Together we will SAVE LIFE"/ Gary Petersen [email protected]
For patients under the care of Dr. Faber, you are 5.9 times more likely to survive 2 years and 1.6 times more likely to survive 4 years, as compared to the average SEER facility. They have provided their transplant experience over the past 5 years, and report a 2 year survival rate of 93.9%* versus the SEER data of 64.1%. They further report their 4 year survival rate of 67.8%* versus the SEER survival rate of 49.2%. Therefore, receiving care through Dr. Faber at the University of Nebraska Medical Center is another excellent find for multiple myeloma patients in the Midwest.
Since maintenance therapy with lenalidomide has only recently been adopted, the reported survival rates includes patient populations which may or may not receive maintenance lenalidomide therapy. Dr. Faber also revealed in his analysis that they are actively following the outcomes of the patients on lenalidomide maintenance in order to determine the impact of lenaldomide mainteance on these reported survival rates, especially the 4 to 5 year survival rate, which of course we all hope will improve outcomes. Dr. Faber included a very impressive bio with his information and I have included it below.
Edward A. Faber Jr., D.O., M.S., Short Biosketch:
Assistant Professor of Internal Medicine in the Hematology/Oncology Division at the University of Nebraska Medical Center since July 2009, after completing hematology / oncology fellowship training at Michigan State University.
Dr. Faber is a NCCN panel member for multiple myeloma, amyloidosis and Waldenstrom’s Macroglobulinemia. He recently has been appointed as an advisory panelist for Amyloidosis on ASCO’s Cancer.Net, Editorial Board’s Lymphoma Panel, as well as the Association of Community Cancer Centers (ACCC) Multiple Myeloma Advisory Committee. Dr. Faber also participates in the following national committees: Alliance for Clinical Trials in Oncology [CALGB] Myeloma Committee, Alliance for Clinical Trials in Oncology [CALGB] Transplant Committee, BMT CTN Myeloma Working Group, CIBMTR Myeloma Working Group. He was recently appointed as Director of UNMC’s M1/M2 Hematology/Oncology Core Course.
He is a principal investigator for all phases of clinical trials, while collaborating with cooperative groups such as Alliance, ECOG, CALGB and BMT CTN, as well as investigator initiated clinical trials. He has a special interest in clinical trials involving early, novel therapies for relapsed / refractory and high risk multiple myeloma. He also pursues translational research by applying nanomedicine to relapsed / refractory myeloma, with his current project involving the use of Pluronic polymers to augment the efficicacy of proteosome inhibitors.
Again we welcome Dr. Faber to the www.myelomasurvival.com community of skilled multiple myeloma specialists.
Best Regards and "Together we will SAVE LIFE"/ Gary Petersen [email protected]
RSS Feed